Get the Stockscreener App
59.27
0.90%
0.53
After Hours:
59.25
-0.02
-0.03%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $59.27, with a volume of 6.03M.
It is up +0.90% in the last 24 hours and up +14.16% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$58.74
Open:
$58.82
24h Volume:
6.03M
Relative Volume:
0.58
Market Cap:
$120.54B
Revenue:
$47.44B
Net Income/Loss:
$-7.26B
P/E Ratio:
15.04
EPS:
3.94
Net Cash Flow:
$13.80B
1W Performance:
+2.40%
1M Performance:
+14.16%
6M Performance:
+43.72%
1Y Performance:
+20.91%
1-Day Range:
$58.78
$59.51
1-Week Range:
$57.47
$60.68
52-Week Range:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.27 | 120.54B | 47.44B | -7.26B | 13.80B | 3.94 |
|
LLY
Lilly Eli Co
|
788.19 | 752.65B | 40.86B | 8.37B | -2.28B | 5.4193 |
|
NVO
Novo Nordisk Adr
|
106.13 | 471.56B | 39.36B | 13.79B | 9.83B | 2.4077 |
|
JNJ
Johnson Johnson
|
155.40 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
|
ABBV
Abbvie Inc
|
183.08 | 323.72B | 55.53B | 5.12B | 15.62B | 3.65 |
|
MRK
Merck Co Inc
|
103.12 | 260.72B | 63.17B | 12.15B | 14.84B | 1.80 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Glenmede Trust Co. NA Lowers Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Qsemble Capital Management LP Sells 12,253 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Loomis Sayles & Co. L P Has $14.36 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Bristol Myers Sues HHS Over Rebate Model in Drug Discount Plan - Bloomberg Law
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Expanding access to lung cancer screening - Bristol Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by D.A. Davidson & CO. - MarketBeat
Bristol Myers Squibb CEO to Present at Citi's 2024 Healthcare Conference | BMY Stock News - StockTitan
Eagle Asset Management Inc. Purchases Shares of 54,691 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb stock boosted by CAR-T success and Camzyos ramp - Investing.com
Associated Banc Corp Sells 14,083 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Sompo Asset Management Co. Ltd. Has $2.58 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Where Will Bristol Myers Squibb Be in 5 Years? - The Motley Fool
Meridian Wealth Management LLC Buys New Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback - Yahoo! Voices
Bristol-Myers Squibb: Expansion into Alzheimer's Disease Psychosis Treatment As A Key Growth Catalyst!Major Drivers - Smartkarma
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Charles Schwab Investment Management Inc. Has $3.16 Billion Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Integrated Investment Consultants LLC Invests $17.49 Million in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
John G Ullman & Associates Inc. Decreases Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Bristol Myers Squibb Stock a Buy? - The Motley Fool
Primecap Management Co. CA Cuts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Commerce Bank Sells 30,241 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Vital Signs: Merck maps Keytruda's next act in the injectables marketplace - FirstWord Pharma
Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Pzena Investment Management LLC Buys 67,409 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Advisors Asset Management Inc. Boosts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Jennison Associates LLC - MarketBeat
Premier Fund Managers Ltd Takes Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
CAMZYOS™ Honoured with the Prix Galien Canada Innovative Product Award - Canada NewsWire
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD - Barchart
J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu - Fierce Biotech
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by PNC Financial Services Group Inc. - MarketBeat
BMS CFO backs “resilient” pharma industry amid RFK’s impending governance - Pharmaceutical Technology
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms - BioSpace
OneAscent Financial Services LLC Purchases Shares of 8,855 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY) - Nasdaq
Bristol Myers to Present 90+ Studies at ASH, Including 5-Year Breyanzi Data | BMY Stock News - StockTitan
Aviance Capital Partners LLC Trims Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by MAI Capital Management - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Natixis Advisors LLC - MarketBeat
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - AOL
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer - Pharmaceutical Technology
Bristol-Myers Squibb: Buy This Bargain Stock Before It's Gone (NYSE:BMY) - Seeking Alpha
Swiss National Bank Boosts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):